Fig. 5

EZH2 expression in DMG and pharmacological inhibition in an in vivo DIPG model. a. Ki-67 and EZH2 expression are shown in representative DMG patient samples (scale bar = 100 µm). b. Correlation plot demonstrating a positive correlation between EZH2 and Ki67 in human DMG patient samples with r = 0.6774, n = 8, p value 0.0649 by a 2 tailed test c. Tazemetostat (EPZ-6438) treatment protocol for Np53fl; ABC KO mice injected with RCAS-PDGF-B, CRE and H3.3K27M virus producing DF1 cells to establish DMG is shown. d. Representative H&E and IHC staining of tumors for K27M, H3K27me3, and Ki-67 from vehicle and Tazemetostat treated mice are shown. Scale bar for H&E and K27M IHC is 500 µm, 100 µm for H3K27me3 IHC, and 20 µm for KI-67 IHC e. Kaplan–Meier survival curve comparison between vehicle and Tazemetostat treated mice is depicted. Median survival for the vehicle group was 46 days and 50 days for the Tazemetostat arm with a p-value of 0.25 by the log-rank test. f. Quantitation of Ki-67 score in both groups is shown, n.s not significant